Adriana Rita Schultz Moreira

Dr. Adriana Rita Schultz Moreira

Department of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg-Essen
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2020 in Liver International
Verified
Journal Article
Open access
PDF file
DRDorothee Römermann
Dorothee Römermann
NANadiea Ansari
Nadiea Ansari
Adriana Rita Schultz MoreiraAdriana Rita Schultz Moreira
Adriana Rita Schultz Moreira
AMAlina Michael
Alina Michael
SMSilke Marhenke
Silke Marhenke
LBLaura Elisa Buitrago-Molina
Laura Elisa Buitrago-Molina
Background and aims: Autophagy is a critical process in cell survival and the maintenance of homeostasis. However, the implementation of therapeutic approaches based on autophagy mechanisms after liver damage is still challenging.Methods: We used a hepatospecific Atg7‐deficient murine model to address this question.Results: We showed that the proliferation and regeneration capacity of Atg7‐deficient hepatocytes was impaired. On the one hand, Atg7‐deficient hepatocytes showed steady‐state hyperproliferation. On the other hand, external triggers such as partial hepatectomy (PHx) or cell transplantation did not induce hepatocellular proliferation or liver repopulation. After PHx, hepatocyte proliferation was strongly decreased, accompanied by high mortality. This increase in mortality could be overcome by pharmacological mTOR inhibition. In accordance with hepatocyte hypoproliferation after damage, Atg7‐deficient hepatocytes failed to repopulate the liver in a hepatic injury model. Atg7‐deficient mice showed hepatic hypertrophy, transient cellular hypertrophy, and high transaminase levels followed by strong perisinusoidal/pericellular fibrosis with age. Their elevated modified hepatic activity index (mHAI) was almost exclusively due to apoptosis without any inflammation. These parameters were associated with variations in the triglyceride content and compromised lipid droplet formation after PHx. Mechanistically, we also observed a modulation of HGF, PAK4, NOTCH3 and YES1, which are proteins involved in cell cycle regulation.Conclusion: We demonstrated the important role of autophagy in the regeneration capacity of hepatocytes. We showed the causative relationship between autophagy and triglycerides that is essential for promoting liver recovery. Finally, pharmacological mTOR inhibition overcame the impact of autophagy deficiency after liver damage and prevented mortality.

Verified
Journal Article
Open access
PDF file
Adriana Rita Schultz MoreiraAdriana Rita Schultz Moreira
Adriana Rita Schultz Moreira
SRSabrina Rüschenbaum
Sabrina Rüschenbaum
SSStefan Schefczyk
Stefan Schefczyk
UHUlrike Hendgen-Cotta
Ulrike Hendgen-Cotta
Tienush RassafTienush Rassaf
Tienush Rassaf
LBLaura Elisa Buitrago-Molina
Laura Elisa Buitrago-Molina
Nonalcoholic fatty liver disease (NAFLD) is quickly becoming the most common liver disease worldwide. Within the NAFLD spectrum, patients with nonalcoholic steatohepatitis (NASH) are at the highest risk of developing cirrhosis and disease progression to hepatocellular carcinoma. To date, therapeutic options for NASH patients have been ineffective, and therefore, new options are urgently needed. Hence, a model system to develop new therapeutic interventions is needed. Here, we introduce two new in vitro models of steatosis induction in HepG2 cells and primary murine hepatocytes. We used a recently discovered novel class of bioactive anti-inflammatory lipids called branched fatty acid esters of hydroxyl fatty acids. Among these bioactive lipids, palmitic-acid-9-hydroxy-stearic-acid (9-PAHSA) is the most promising as a representative nondrug therapy based on dietary supplements or nutritional modifications. In this study, we show a therapeutic effect of 9-PAHSA on lipotoxicity in steatotic primary hepatocytes and HepG2 cells. This could be shown be increased viability and decreased steatosis. Furthermore, we could demonstrate a preventive effect in HepG2 cells. The outcome of 9-PAHSA administration is both preventative and therapeutically effective for hepatocytes with limited damage. In conclusion, bioactive lipids like 9-PAHSA offer new hope for prevention or treatment in patients with fatty liver and steatosis.

11 November 2015 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
NBNelly Janet Trujillo Bagnasco
Nelly Janet Trujillo Bagnasco
Adriana Rita Schultz MoreiraAdriana Rita Schultz Moreira
Adriana Rita Schultz Moreira
MMMaisa Martins
Maisa Martins
DFDayana Farias
Dayana Farias
GKGilberto Kac
Gilberto Kac